~~<i id='229F1E0290'><strike id='229F1E0290'><tt id='229F1E0290'><pre id='229F1E0290'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

knowledge

author：explore 2025-10-02 23:47:20 - browse：7253

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： U.S. death rates show how politics are affecting public health

hotspot

leisure time

Wikipedia

leisure time

hotspot

entertainment

Underamicroscope,humanprostatecancercells,colorizedinblue,appearinanairbubble.AdobeAnearly-stageclin

WSS

Biotech incubator Curie.Bio graduates its first startup

Medicare will require more price transparency from hospitals

Abortion clinic in Cancun will cater to Americans

FDA approves Recor Medical high blood pressure device

Louisiana bill approved classifying abortion pills as controlled substances

Removing probiotics from the NICU could threaten preemies' health

hotspot

knowledge

hotspot

Jerome Adams on the need for new antivirals for Covid

Achieving telehealth equity for people with hearing loss

ChatGPT in medicine: STAT answers readers' burning questions

A clever new way to fix Medicaid and graduate medical education

Malaria cases in Florida and Texas: Here’s what you need to know

Ambulance rides for just $100? Advisers want major billing fixes

Cancer drug shortages should be causing more outrage

Will General Catalyst be the first of many hospital takeovers?

Anesthesiologist group: stop taking Ozempic before surgery

The Bio Revolution is changing business and society

leisure time

Biotech incubator Curie.Bio graduates its first startup

The Sacklers, horror, and ‘The Fall of the House of Usher’

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

FDA approves potent Eli Lilly obesity drug, Zepbound

Congress: Prevent baby formula shortages by passing a new bill

J&J reports mixed data on next

Wikipedia

leisure time

hotspot

entertainment